Ambient-Temperature Extraction-Free One-Pot CRISPR Detection of Mycobacterium tuberculosis

Technical Summary: Ambient-Temperature Extraction-Free One-Pot CRISPR Detection of Mycobacterium tuberculosis

Problem Statement
Current molecular diagnostics for Mycobacterium tuberculosis (MTB), such as GeneXpert and culture, face significant barriers to implementation in resource-limited and point-of-care (POC) settings. These barriers include the requirement for complex nucleic acid extraction procedures, specialized laboratory infrastructure, reliable electricity, and trained personnel. While CRISPR-based diagnostics offer high sensitivity and specificity, existing workflows for MTB detection typically still rely on conventional nucleic acid extraction, multiple processing steps, and laboratory-based instrumentation, limiting their utility as rapid, decentralized tests.

Methodology
The authors developed a streamlined, "one-pot" assay that integrates ambient-temperature chemical lysis, recombinase polymerase amplification (RPA), and CRISPR-Cas12a detection within a single closed-tube workflow.

• Sample Preparation: The assay utilizes an extraction-free protocol. Sputum specimens are mixed 1:1 with a matrix-tolerant lysis buffer containing Triton X-100, Tween-20, and dithiothreitol (DTT) at an alkaline pH. This mixture is incubated at ambient temperature (22–25°C) for 5 minutes. The detergents disrupt the mycolic acid cell wall, while DTT reduces sputum viscosity by breaking disulfide bonds in mucin. No centrifugation, heating, or column purification is performed; 2 μL of the crude lysate is directly added to the reaction.
• Amplification and Detection: The reaction targets a conserved 140-bp region of the MTB-specific IS6110 insertion sequence. The 25 μL reaction mixture includes RPA primers, LbCas12a, crRNA, and a FAM/biotin-labeled ssDNA reporter. To prevent premature cleavage, the Cas12a-crRNA complex is added after an initial 10-minute amplification period via tube inversion.
• Readout: Detection is visualized via lateral flow assay (LFA). Activated Cas12a cleaves the reporter upon target recognition, generating a test band. Results are captured within 30 minutes of sample initiation.
• Validation: Analytical performance was assessed using serially diluted MTB genomic DNA (H37Rv strain) and spiked sputum. Clinical validation involved 100 archived sputum specimens (50 MTB-positive, 50 MTB-negative) compared against GeneXpert MTB/RIF and qPCR reference standards.

Key Contributions
The study introduces a diagnostic platform that uniquely integrates four specific workflow innovations into a single system:

1. Direct analysis of minimally processed sputum.
2. Complete elimination of nucleic acid extraction.
3. A one-pot, closed-tube RPA-CRISPR-Cas12a format.
4. Entirely ambient-temperature sample processing (no heating required).

The authors note that while previous CRISPR-based MTB assays have addressed some of these features individually, this is the first to combine all four into a single workflow.

Results

• Analytical Specificity: The assay demonstrated 100% specificity, detecting MTB DNA without cross-reactivity against non-tuberculous mycobacteria (M. avium, M. kansasii) or common respiratory pathogens (S. aureus, S. pneumoniae).
• Analytical Sensitivity:
  • Using purified DNA, the limit of detection (LoD) was 10 copies per reaction.
  • Using the extraction-free crude sputum lysate workflow, the LoD was 100 copies per reaction. This represents a one-log reduction in sensitivity compared to purified DNA but remains within clinically relevant ranges.
• Clinical Performance: In the validation cohort of 100 specimens:
  • Sensitivity: 96.0% (48/50 positive cases detected).
  • Specificity: 98.0% (49/50 negative controls correctly identified).
  • Agreement: The assay showed 97.0% concordance with reference methods (GeneXpert/qPCR) and a Cohen's κ coefficient of 0.94.
  • Bacterial Burden: Sensitivity was 100% for high (Ct <25) and moderate (Ct 25–30) bacterial burdens. Sensitivity decreased to 80% for low-burden specimens (Ct >30), where two false negatives occurred.
  • ROC Analysis: The area under the curve (AUC) was 0.982, indicating excellent diagnostic discrimination.

Significance and Claims
The paper claims that this study demonstrates the feasibility of performing rapid, high-performance molecular diagnostics for TB directly from sputum without the need for nucleic acid extraction or complex laboratory infrastructure. By maintaining high diagnostic accuracy (96% sensitivity, 98% specificity) while eliminating extraction steps and heating requirements, the platform addresses critical bottlenecks for POC testing.

The authors conclude that this approach "may facilitate future development of rapid molecular diagnostics for POC and resource-limited settings." They emphasize that the ability to detect MTB directly from minimally processed sputum supports the viability of a simplified, sample-to-answer molecular diagnostic platform.

Limitations Acknowledged
The authors modestly note several limitations:

• The study utilized archived specimens under controlled conditions; prospective validation with fresh specimens is required.
• The sample size was modest and derived from a limited number of sites.
• Performance in specific subgroups (smear-negative, paucibacillary, pediatric, and extrapulmonary TB) requires further evaluation.
• Long-term stability of reagents under varying environmental conditions has not yet been tested.